The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has officially granted marketing authorization for lenacapavir (branded as Yeytuo) for... Read more
Tag: #Global Trends
A New Chapter in Obesity Management: The Emergence of Oral Weight-Loss Medications
The healthcare industry has reached a significant milestone with the FDA's official approval of the tablet version of semaglutide (Wegovy).... Read more
White House Secures Pricing Accords with Nine Additional Pharmaceutical Giants
In a major step toward implementing the "Most-Favored-Nation" (MFN) pricing policy, the Trump administration has announced individual agreements with nine... Read more
Korean Bio-Pharma Giant Establishes First Manufacturing Foothold in the United States
Samsung Biologics has secured a $280 million deal to acquire GSK’s manufacturing facilities located in Rockville, Maryland. This strategic move... Read more
Obesity Treatment Frontier: FDA Approves First-Ever Oral GLP-1 Tablet
The global healthcare market has reached a historic milestone with the FDA's official approval of the oral tablet formulation of... Read more
Harbour inks $90 million antibody deal with bristol myers squibb
Harbour BioMed has officially entered into a strategic partnership with Bristol Myers Squibb (BMS) to jointly develop advanced therapeutic antibodies.... Read more
Fda approves next-generation biologic for severe asthma treatment
The U.S. Food and Drug Administration (FDA) has officially approved Exdensur (depemokimab), an add-on biologic maintenance treatment for severe asthma... Read more
Galux and boehringer ingelheim to jointly explore ai in precision protein design
Galux, a South Korean biotech firm pioneering AI-driven protein therapeutics discovery, has formally entered into a research agreement with Boehringer... Read more
Gilead sciences appoints new head of global legal and compliance
Gilead Sciences Inc. has officially announced the appointment of Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance.... Read more









